# Nurix Therapeutics (NRIX) — News

NRIX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/nrix/news

## Recent headlines

- [Nurix Therapeutics, Inc.: Oppenheimer raises target price to $32 from $28](https://www.ainvest.com/news/nurix-therapeutics-oppenheimer-raises-target-price-32-28-2610) — AInvest Wire, Oct 13, 2026
- [Nurix Therapeutics, Inc.: Stifel raises target price to $41 from $40](https://www.ainvest.com/news/nurix-therapeutics-stifel-raises-target-price-41-40-2610) — AInvest Wire, Oct 13, 2026
  Stifel has revised its price target for Nurix Therapeutics, Inc. (NURX) to $41 from $40, reflecting updated expectations for the company’s financial performance and strategic outlook [1]. The adjustment follows a comprehensive review of Nurix’s recent business developments and market positioning.…
- [Nurix Therapeutics Q3 revenue USD 673.064 million](https://www.ainvest.com/news/nurix-therapeutics-q3-revenue-usd-673-064-million-2610) — AInvest Wire, Oct 12, 2026
  Nurix Therapeutics reported third-quarter revenue of $673.064 million, reflecting continued growth in its targeted protein degradation platform and strategic collaborations. The company has been advancing its pipeline through partnerships with major pharmaceutical firms, including Roche, Gilead…
- [Nurix 3Q R&D expenses $79.3M, est. $77.1M](https://www.ainvest.com/news/nurix-3q-expenses-79-3m-est-77-1m-2610) — AInvest Wire, Oct 12, 2026
  Nurix Therapeutics, Inc. (Nasdaq: NRIX) reported research and development (R&D) expenses of $79.3 million for the third quarter of fiscal 2024, exceeding the estimated $77.1 million for the period. The increase in R&D spending reflects the company’s continued investment in its clinical trial…
- [Nurix 3Q rev. $19.9M est. $24.4M](https://www.ainvest.com/news/nurix-3q-rev-19-9m-est-24-4m-2610) — AInvest Wire, Oct 12, 2026
  Nurix Therapeutics, Inc. (Nasdaq: NRIX) reported financial results for the first quarter of fiscal 2026, with revenue coming in below estimates. Revenue for the three months ended February 28, 2026, was $6.3 million, compared to $18.5 million in the same period in 2025. This decline was primarily…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).